Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix

Hugh M. Shingleton, Seng Jaw Soong, Mark S. Gelder, Kenneth D Hatch, Vicki V. Baker, Maxwell J. Austin

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Between September 1969 and January 1, 1986, 143 pelvic exenterations for recurrent cervical cancer were performed by the gynecologic oncologists at the University of Alabama at Birmingham. of this group, 78 patients underwent total pelvic exenteration, 63 patients had anterior exenteration, and two had posterior exenteration. The overall operative mortality rate was 6.3%, mostly associated with total pelvic exenteration. The 5-year survival rates were 50% overall, 63% with anterior exenteration and 42% with total exenteration. Univariate and multivariate analyses were performed to identify clinical and histopathologic factors predictive of prolonged survival. Using three clinical factors (duration from initial radiation therapy to exenteration, size of the central mass, and presence of preoperative sidewall fixation), low-, intermediate-, and high-risk groups were constructed; the 5-year survival rates for these groups were 82, 46, and 0%, respectively. Inclusion of one histopathologic factor (margin status of the surgical specimen) added to the ability to predict 2- and 5-year survival rates. The best candidates for cure by pelvic exenteration were those with recurrent small (less than 3 cm), mobile central masses who were a year or longer from the time of their previous radiation therapy. Attempts to resect bulky pelvic recurrences that impinge on the pelvic sidewall, especially in the case of persistent or early recurrent disease (within 6 months), or continuation of exenterative procedures in women known to have nodal metastases or extrapelvic spread, are generally futile. For those women falling between the two extremes, sound clinical and operative judgment is imperative in regard to selecting the treatment offering the best quality of life.

Original languageEnglish (US)
Pages (from-to)1027-1034
Number of pages8
JournalAmerican Journal of Obstetrics and Gynecology
Volume73
Issue number6
StatePublished - 1989
Externally publishedYes

Fingerprint

Pelvic Exenteration
Pelvic Neoplasms
Uterine Cervical Neoplasms
Recurrence
Survival
Survival Rate
Radiotherapy
Aptitude
Multivariate Analysis
Quality of Life
Neoplasm Metastasis
Mortality

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. / Shingleton, Hugh M.; Soong, Seng Jaw; Gelder, Mark S.; Hatch, Kenneth D; Baker, Vicki V.; Austin, Maxwell J.

In: American Journal of Obstetrics and Gynecology, Vol. 73, No. 6, 1989, p. 1027-1034.

Research output: Contribution to journalArticle

Shingleton, Hugh M. ; Soong, Seng Jaw ; Gelder, Mark S. ; Hatch, Kenneth D ; Baker, Vicki V. ; Austin, Maxwell J. / Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. In: American Journal of Obstetrics and Gynecology. 1989 ; Vol. 73, No. 6. pp. 1027-1034.
@article{075d22da3a8d49f0ac34ad264f96c535,
title = "Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix",
abstract = "Between September 1969 and January 1, 1986, 143 pelvic exenterations for recurrent cervical cancer were performed by the gynecologic oncologists at the University of Alabama at Birmingham. of this group, 78 patients underwent total pelvic exenteration, 63 patients had anterior exenteration, and two had posterior exenteration. The overall operative mortality rate was 6.3{\%}, mostly associated with total pelvic exenteration. The 5-year survival rates were 50{\%} overall, 63{\%} with anterior exenteration and 42{\%} with total exenteration. Univariate and multivariate analyses were performed to identify clinical and histopathologic factors predictive of prolonged survival. Using three clinical factors (duration from initial radiation therapy to exenteration, size of the central mass, and presence of preoperative sidewall fixation), low-, intermediate-, and high-risk groups were constructed; the 5-year survival rates for these groups were 82, 46, and 0{\%}, respectively. Inclusion of one histopathologic factor (margin status of the surgical specimen) added to the ability to predict 2- and 5-year survival rates. The best candidates for cure by pelvic exenteration were those with recurrent small (less than 3 cm), mobile central masses who were a year or longer from the time of their previous radiation therapy. Attempts to resect bulky pelvic recurrences that impinge on the pelvic sidewall, especially in the case of persistent or early recurrent disease (within 6 months), or continuation of exenterative procedures in women known to have nodal metastases or extrapelvic spread, are generally futile. For those women falling between the two extremes, sound clinical and operative judgment is imperative in regard to selecting the treatment offering the best quality of life.",
author = "Shingleton, {Hugh M.} and Soong, {Seng Jaw} and Gelder, {Mark S.} and Hatch, {Kenneth D} and Baker, {Vicki V.} and Austin, {Maxwell J.}",
year = "1989",
language = "English (US)",
volume = "73",
pages = "1027--1034",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix

AU - Shingleton, Hugh M.

AU - Soong, Seng Jaw

AU - Gelder, Mark S.

AU - Hatch, Kenneth D

AU - Baker, Vicki V.

AU - Austin, Maxwell J.

PY - 1989

Y1 - 1989

N2 - Between September 1969 and January 1, 1986, 143 pelvic exenterations for recurrent cervical cancer were performed by the gynecologic oncologists at the University of Alabama at Birmingham. of this group, 78 patients underwent total pelvic exenteration, 63 patients had anterior exenteration, and two had posterior exenteration. The overall operative mortality rate was 6.3%, mostly associated with total pelvic exenteration. The 5-year survival rates were 50% overall, 63% with anterior exenteration and 42% with total exenteration. Univariate and multivariate analyses were performed to identify clinical and histopathologic factors predictive of prolonged survival. Using three clinical factors (duration from initial radiation therapy to exenteration, size of the central mass, and presence of preoperative sidewall fixation), low-, intermediate-, and high-risk groups were constructed; the 5-year survival rates for these groups were 82, 46, and 0%, respectively. Inclusion of one histopathologic factor (margin status of the surgical specimen) added to the ability to predict 2- and 5-year survival rates. The best candidates for cure by pelvic exenteration were those with recurrent small (less than 3 cm), mobile central masses who were a year or longer from the time of their previous radiation therapy. Attempts to resect bulky pelvic recurrences that impinge on the pelvic sidewall, especially in the case of persistent or early recurrent disease (within 6 months), or continuation of exenterative procedures in women known to have nodal metastases or extrapelvic spread, are generally futile. For those women falling between the two extremes, sound clinical and operative judgment is imperative in regard to selecting the treatment offering the best quality of life.

AB - Between September 1969 and January 1, 1986, 143 pelvic exenterations for recurrent cervical cancer were performed by the gynecologic oncologists at the University of Alabama at Birmingham. of this group, 78 patients underwent total pelvic exenteration, 63 patients had anterior exenteration, and two had posterior exenteration. The overall operative mortality rate was 6.3%, mostly associated with total pelvic exenteration. The 5-year survival rates were 50% overall, 63% with anterior exenteration and 42% with total exenteration. Univariate and multivariate analyses were performed to identify clinical and histopathologic factors predictive of prolonged survival. Using three clinical factors (duration from initial radiation therapy to exenteration, size of the central mass, and presence of preoperative sidewall fixation), low-, intermediate-, and high-risk groups were constructed; the 5-year survival rates for these groups were 82, 46, and 0%, respectively. Inclusion of one histopathologic factor (margin status of the surgical specimen) added to the ability to predict 2- and 5-year survival rates. The best candidates for cure by pelvic exenteration were those with recurrent small (less than 3 cm), mobile central masses who were a year or longer from the time of their previous radiation therapy. Attempts to resect bulky pelvic recurrences that impinge on the pelvic sidewall, especially in the case of persistent or early recurrent disease (within 6 months), or continuation of exenterative procedures in women known to have nodal metastases or extrapelvic spread, are generally futile. For those women falling between the two extremes, sound clinical and operative judgment is imperative in regard to selecting the treatment offering the best quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0024401234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024401234&partnerID=8YFLogxK

M3 - Article

C2 - 2726106

AN - SCOPUS:0024401234

VL - 73

SP - 1027

EP - 1034

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -